Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?
作者信息
Dal-Ré Rafael
机构信息
Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain.
出版信息
Br J Clin Pharmacol. 2021 May;87(5):2405-2406. doi: 10.1111/bcp.14828. Epub 2021 Mar 24.
Abstract
摘要
相似文献
1
Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?阿斯利康能否提供其新冠疫苗在老年人中的临床试验疗效数据？
Br J Clin Pharmacol. 2021 May;87(5):2405-2406. doi: 10.1111/bcp.14828. Epub 2021 Mar 24.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒（灭活）疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.
4
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
5
Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths.牛津-阿斯利康（ChAdOx1 CoV-19）疫苗对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）病例、住院、变异类型和死亡的疗效。
Eur Rev Med Pharmacol Sci. 2023 Oct;27(20):10133-10143. doi: 10.26355/eurrev_202310_34193.
6
COVID-19 vaccine trials: The use of active controls and non-inferiority studies.COVID-19 疫苗试验：活性对照和非劣效性研究的应用。
Clin Trials. 2021 Jun;18(3):335-342. doi: 10.1177/1740774520988244. Epub 2021 Feb 3.
7
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
8
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.临床试验中 SARS-CoV-2 疫苗的免疫原性和安全性。
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
9
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review.辉瑞/生物技术、莫德纳和阿斯利康疫苗对 SARS-CoV-2 的疫苗效力：系统评价。
Front Public Health. 2023 Oct 24;11:1229716. doi: 10.3389/fpubh.2023.1229716. eCollection 2023.
10
Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials.某些新冠疫苗比其他疫苗更好吗？解读和比较疫苗试验中的疗效评估。
Clin Infect Dis. 2022 Jan 29;74(2):352-358. doi: 10.1093/cid/ciab213.
引用本文的文献
1
Comparison of side effects of the dose-1 of AstraZeneca and Sinopharm vaccines in patients with multiple sclerosis in Kermanshah, Iran (2021).伊朗克尔曼沙阿地区多发性硬化症患者中阿斯利康疫苗和国药疫苗1剂次副作用的比较（2021年）
Curr J Neurol. 2023 Jan 5;22(1):8-15. doi: 10.18502/cjn.v22i1.12611.
2
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans.阿斯利康 COVID-19 疫苗从首次给人类接种到现在已经过去了 12 个月的曲折历程。
Therapie. 2023 May-Jun;78(3):293-302. doi: 10.1016/j.therap.2022.07.003. Epub 2022 Jul 13.
3
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.聚焦于现有 COVID-19 疫苗的技术、机制、安全性和有效性的综述。
Int Immunopharmacol. 2021 Nov;100:108162. doi: 10.1016/j.intimp.2021.108162. Epub 2021 Sep 17.
4
Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.公众对监管决策的信任：欧洲药品管理局与阿斯利康新冠疫苗标签
Vaccine. 2021 Jul 5;39(30):4029-4031. doi: 10.1016/j.vaccine.2021.05.095. Epub 2021 Jun 4.
本文引用的文献
1
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
2
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
3
Trial participants' rights after authorisation of COVID-19 vaccines.新冠疫苗获批后试验参与者的权利。
Lancet Respir Med. 2021 Apr;9(4):e30-e31. doi: 10.1016/S2213-2600(21)00044-8. Epub 2021 Jan 18.
4
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
Zotero 插件